提升NAD+水平通过短链脱氢酶/还原酶蛋白缓解心力衰竭,不依赖线粒体蛋白去乙酰化
该研究在压力负荷诱导的心力衰竭小鼠模型中,于心功能已受损后给予烟酰胺核糖苷治疗,发现其改善线粒体功能并延缓心衰进展,且该获益不依赖Sirt3介导的线粒体蛋白去乙酰化。机制上,NAD+提升通过激活SDR家族蛋白(如Mrpp2)改善线粒体DNA转录本加工和电子传递链功能,并激活视黄醇代谢途径的RXRα/PPARα信号恢复线粒体氧化代谢。人衰竭心脏中亦观察到Mrpp2下调和线粒体核糖核酸酶P受损。
要点
- NAD+提升治疗在已建立心功能障碍的小鼠中仍可改善线粒体功能并延缓心衰进展。
- 该获益不依赖Sirt3介导的线粒体蛋白去乙酰化,SIRT3敲除小鼠与野生型小鼠获益相似。
- SDR家族蛋白(如Mrpp2)是NAD+治疗的重要分子靶点,人衰竭心脏中亦见Mrpp2下调。
核心结论
- 提升NAD+水平通过激活SDR蛋白改善线粒体功能并缓解心力衰竭,且不依赖Sirt3介导的线粒体蛋白去乙酰化。
- NAD+基础治疗对已存在的心力衰竭仍可能有效。
研究设计与样本
- 在SIRT3敲除小鼠和野生型小鼠中通过压力负荷诱导心功能障碍,比较烟酰胺核糖苷治疗的反应。
- 为模拟治疗策略,在已建立心功能障碍的小鼠中启动治疗。
主要发现
- 烟酰胺核糖苷改善线粒体功能并延缓心衰进展,野生型和SIRT3敲除小鼠获益相似。
- 提升NAD+水平改善NAD(H)氧化还原敏感的SDR家族蛋白功能。
- 上调Mrpp2改善线粒体DNA转录本加工和电子传递链功能。
- 激活视黄醇代谢通路中的SDR刺激RXRα/PPARα信号并恢复线粒体氧化代谢。
- 人衰竭心脏中观察到Mrpp2下调和线粒体核糖核酸酶P受损。
临床怎么用
- NAD+基础治疗可能适用于已出现症状的心力衰竭患者,而非仅限预处理。
- SDR蛋白(如Mrpp2)可作为NAD+治疗心力衰竭的潜在分子靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Strategies to increase cellular NAD+ (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD+-based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation of sirtuin, especially Sirt3 (sirtuin 3), and mitochondrial protein acetylation. METHODS: We induced cardiac dysfunction by pressure overload in SIRT3-deficient (knockout) mice and compared their response with nicotinamide riboside chloride treatment with wild-type mice. To model a therapeutic approach, we initiated the treatment in mice with established cardiac dysfunction. RESULTS: We found nicotinamide riboside chloride improved mitochondrial function and blunted heart failure progression. Similar benefits were observed in wild-type and knockout mice. Boosting NAD+ level improved the function of NAD(H) redox-sensitive SDR (short-chain dehydrogenase/reductase) family proteins. Upregulation of Mrpp2 (mitochondrial ribonuclease P protein 2), a multifunctional SDR protein and a subunit of mitochondrial ribonuclease P, improves mitochondrial DNA transcripts processing and electron transport chain function. Activation of SDRs in the retinol metabolism pathway stimulates RXRα (retinoid X receptor α)/PPARα (proliferator-activated receptor α) signaling and restores mitochondrial oxidative metabolism. Downregulation of Mrpp2 and impaired mitochondrial ribonuclease P were found in human failing hearts, suggesting a shared mechanism of defective mitochondrial biogenesis in mouse and human heart failure. CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD+-based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD+-based therapy for heart failure. The data also show that NAD+-based therapy can be useful in pre-existing heart failure.
引用
- Walker, Chen, Yadav, et al. Raising NAD+ Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation. Circulation. 2023. PMID: 37965787. doi:10.1161/CIRCULATIONAHA.123.066039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。